SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation on June 5, 2014. The registrant is incorporated in Delaware and headquartered in Salt Lake City, Utah. Note: The request metadata referenced "Sintx Technologies, Inc.," but the filing text explicitly identifies the registrant as Amedica Corporation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes
- Cessation of Product Distribution: On June 5, 2014, the company announced it will cease the distribution of amniotic derived allograft products.
- Contract Termination: This action involves terminating a distribution agreement with a third-party supplier.
Outlook, Risks, and Management Commentary
Management issued a press release (Exhibit 99.1) detailing the decision to stop distribution. The filing does not contain forward-looking guidance, specific risk factors, or details on contingencies beyond the immediate cessation of the product line. The strategic rationale and financial impact of this decision are not quantified in the text of the 8-K.
Investor Verification Checklist
- Verify the specific financial impact of ceasing amniotic derived allograft product distribution on future revenue streams.
- Review the attached press release (Exhibit 99.1) for the strategic reasoning behind the termination of the supplier agreement.
- Confirm if there are any remaining liabilities or termination fees associated with the third-party supplier agreement.
- Assess whether this product line was a material portion of the company's overall business operations.